An immune-competent, replication-permissive Syrian Hamster glioma model for evaluating Delta-24-RGD oncolytic adenovirus

Abstract Background Oncolytic adenoviruses are promising new treatments against solid tumors, particularly for glioblastoma (GBM), and preclinical models are required to evaluate the mechanisms of efficacy. However, due to the species selectivity of adenovirus, there is currently no single animal mo...

Full description

Saved in:
Bibliographic Details
Published inNeuro-oncology (Charlottesville, Va.) Vol. 23; no. 11; pp. 1911 - 1921
Main Authors Phillips, Lynette M, Li, Shoudong, Gumin, Joy, Daou, Marc, Ledbetter, Daniel, Yang, Jing, Singh, Sanjay, Parker Kerrigan, Brittany C, Hossain, Anwar, Yuan, Ying, Gomez-Manzano, Candelaria, Fueyo, Juan, Lang, Frederick F
Format Journal Article
LanguageEnglish
Published US Oxford University Press 02.11.2021
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Abstract Background Oncolytic adenoviruses are promising new treatments against solid tumors, particularly for glioblastoma (GBM), and preclinical models are required to evaluate the mechanisms of efficacy. However, due to the species selectivity of adenovirus, there is currently no single animal model that supports viral replication, tumor oncolysis, and a virus-mediated immune response. To address this gap, we took advantage of the Syrian hamster to develop the first intracranial glioma model that is both adenovirus replication-permissive and immunocompetent. Methods We generated hamster glioma stem-like cells (hamGSCs) by transforming hamster neural stem cells with hTERT, simian virus 40 large T antigen, and h-RasV12. Using a guide-screw system, we generated an intracranial tumor model in the hamster. The efficacy of the oncolytic adenovirus Delta-24-RGD was assessed by survival studies, and tumor-infiltrating lymphocytes (TILs) were evaluated by flow cytometry. Results In vitro, hamGSCs supported viral replication and were susceptible to Delta-24-RGD mediated cell death. In vivo, hamGSCs consistently developed into highly proliferative tumors resembling high-grade glioma. Flow cytometric analysis of hamster gliomas revealed significantly increased T-cell infiltration in Delta-24-RGD infected tumors, indicative of immune activation. Treating tumor-bearing hamsters with Delta-24-RGD led to significantly increased survival compared to hamsters treated with phosphate buffered saline (PBS). Conclusions This adenovirus-permissive, immunocompetent hamster glioma model overcomes the limitations of previous model systems and provides a novel platform to study the interactions between tumor cells, the host immune system, and oncolytic adenoviral therapy; understanding of which will be critical to implementing oncolytic adenovirus in the clinic.
AbstractList Abstract Background Oncolytic adenoviruses are promising new treatments against solid tumors, particularly for glioblastoma (GBM), and preclinical models are required to evaluate the mechanisms of efficacy. However, due to the species selectivity of adenovirus, there is currently no single animal model that supports viral replication, tumor oncolysis, and a virus-mediated immune response. To address this gap, we took advantage of the Syrian hamster to develop the first intracranial glioma model that is both adenovirus replication-permissive and immunocompetent. Methods We generated hamster glioma stem-like cells (hamGSCs) by transforming hamster neural stem cells with hTERT, simian virus 40 large T antigen, and h-RasV12. Using a guide-screw system, we generated an intracranial tumor model in the hamster. The efficacy of the oncolytic adenovirus Delta-24-RGD was assessed by survival studies, and tumor-infiltrating lymphocytes (TILs) were evaluated by flow cytometry. Results In vitro, hamGSCs supported viral replication and were susceptible to Delta-24-RGD mediated cell death. In vivo, hamGSCs consistently developed into highly proliferative tumors resembling high-grade glioma. Flow cytometric analysis of hamster gliomas revealed significantly increased T-cell infiltration in Delta-24-RGD infected tumors, indicative of immune activation. Treating tumor-bearing hamsters with Delta-24-RGD led to significantly increased survival compared to hamsters treated with phosphate buffered saline (PBS). Conclusions This adenovirus-permissive, immunocompetent hamster glioma model overcomes the limitations of previous model systems and provides a novel platform to study the interactions between tumor cells, the host immune system, and oncolytic adenoviral therapy; understanding of which will be critical to implementing oncolytic adenovirus in the clinic.
BACKGROUNDOncolytic adenoviruses are promising new treatments against solid tumors, particularly for glioblastoma (GBM), and preclinical models are required to evaluate the mechanisms of efficacy. However, due to the species selectivity of adenovirus, there is currently no single animal model that supports viral replication, tumor oncolysis, and a virus-mediated immune response. To address this gap, we took advantage of the Syrian hamster to develop the first intracranial glioma model that is both adenovirus replication-permissive and immunocompetent. METHODSWe generated hamster glioma stem-like cells (hamGSCs) by transforming hamster neural stem cells with hTERT, simian virus 40 large T antigen, and h-RasV12. Using a guide-screw system, we generated an intracranial tumor model in the hamster. The efficacy of the oncolytic adenovirus Delta-24-RGD was assessed by survival studies, and tumor-infiltrating lymphocytes (TILs) were evaluated by flow cytometry. RESULTSIn vitro, hamGSCs supported viral replication and were susceptible to Delta-24-RGD mediated cell death. In vivo, hamGSCs consistently developed into highly proliferative tumors resembling high-grade glioma. Flow cytometric analysis of hamster gliomas revealed significantly increased T-cell infiltration in Delta-24-RGD infected tumors, indicative of immune activation. Treating tumor-bearing hamsters with Delta-24-RGD led to significantly increased survival compared to hamsters treated with phosphate buffered saline (PBS). CONCLUSIONSThis adenovirus-permissive, immunocompetent hamster glioma model overcomes the limitations of previous model systems and provides a novel platform to study the interactions between tumor cells, the host immune system, and oncolytic adenoviral therapy; understanding of which will be critical to implementing oncolytic adenovirus in the clinic.
Author Phillips, Lynette M
Ledbetter, Daniel
Gomez-Manzano, Candelaria
Lang, Frederick F
Parker Kerrigan, Brittany C
Fueyo, Juan
Singh, Sanjay
Daou, Marc
Yuan, Ying
Gumin, Joy
Yang, Jing
Li, Shoudong
Hossain, Anwar
AuthorAffiliation 1 Department of Neurosurgery, The University of Texas MD Anderson Cancer Center , Houston, Texas , USA
2 The Brain Tumor Center, The University of Texas MD Anderson Cancer Center , Houston, Texas , USA
3 Department of Biostatistics, The University of Texas MD Anderson Cancer Center , Houston, Texas , USA
4 Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center , Houston, Texas , USA
AuthorAffiliation_xml – name: 2 The Brain Tumor Center, The University of Texas MD Anderson Cancer Center , Houston, Texas , USA
– name: 4 Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center , Houston, Texas , USA
– name: 3 Department of Biostatistics, The University of Texas MD Anderson Cancer Center , Houston, Texas , USA
– name: 1 Department of Neurosurgery, The University of Texas MD Anderson Cancer Center , Houston, Texas , USA
Author_xml – sequence: 1
  givenname: Lynette M
  surname: Phillips
  fullname: Phillips, Lynette M
  organization: Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
– sequence: 2
  givenname: Shoudong
  surname: Li
  fullname: Li, Shoudong
  organization: Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
– sequence: 3
  givenname: Joy
  surname: Gumin
  fullname: Gumin, Joy
  organization: Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
– sequence: 4
  givenname: Marc
  surname: Daou
  fullname: Daou, Marc
  organization: Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
– sequence: 5
  givenname: Daniel
  surname: Ledbetter
  fullname: Ledbetter, Daniel
  organization: Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
– sequence: 6
  givenname: Jing
  surname: Yang
  fullname: Yang, Jing
  organization: Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
– sequence: 7
  givenname: Sanjay
  surname: Singh
  fullname: Singh, Sanjay
  organization: Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
– sequence: 8
  givenname: Brittany C
  surname: Parker Kerrigan
  fullname: Parker Kerrigan, Brittany C
  organization: Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
– sequence: 9
  givenname: Anwar
  surname: Hossain
  fullname: Hossain, Anwar
  organization: Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
– sequence: 10
  givenname: Ying
  orcidid: 0000-0003-3163-480X
  surname: Yuan
  fullname: Yuan, Ying
  organization: Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
– sequence: 11
  givenname: Candelaria
  surname: Gomez-Manzano
  fullname: Gomez-Manzano, Candelaria
  organization: The Brain Tumor Center, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
– sequence: 12
  givenname: Juan
  surname: Fueyo
  fullname: Fueyo, Juan
  organization: The Brain Tumor Center, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
– sequence: 13
  givenname: Frederick F
  surname: Lang
  fullname: Lang, Frederick F
  email: flang@mdanderson.org
  organization: Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
BookMark eNqFUctqHDEQFMEm9tq55qxjAtFaj9E8LgHjNxgMTnwWWk3PRkGPiTSzeP8-sncx-ORTN3RVdXfVAh2EGAChr4wuGe3EWYA5BnMWol4x3n5Cx0xyQWRb1wevPSetZM0RWuT8l1LOZM0-oyNRUdl1nB2j5_OArfdzAGKiH2GCMP3ACUZnjZ5sDGSE5G3OdgP41zZZHfCt9nmChNfORq-xjz04PMSEYaPdXFhhjS_BTZrwijzeXOJyYXTbyRqsewhxY9OcT9HhoF2GL_t6gp6ur35f3JL7h5u7i_N7YirKJiLK9U0jWKUpG7qXBzitTbMa-LAyXW9aKQTt-5qaoaXFAwF9Ax2IuoK2G4pDJ-jnTnecVx56U_5L2qkxWa_TVkVt1ftJsH_UOm5UK2shmCwC3_YCKf6bIU-q2GHAOR0gzllxKWTLm6ZqCnS5g5oUc04wvK1hVL3EpXZxqX1chfB9R4jz-BH2PwB6nGc
CitedBy_id crossref_primary_10_3390_ijms25095007
crossref_primary_10_3389_fimmu_2023_1126969
crossref_primary_10_3389_fimmu_2023_1060540
crossref_primary_10_1007_s12094_022_02830_x
crossref_primary_10_3389_fonc_2024_1423143
Cites_doi 10.1080/2162402X.2017.1358839
10.1007/s11060-017-2395-y
10.1200/JCO.2017.77.3192
10.1158/0008-5472.CAN-17-0468
10.3171/jns.2000.92.2.0326
10.1128/MCB.25.15.6464-6474.2005
10.1093/infdis/jiv203
10.1093/neuonc/noy075
10.1093/brain/aww046
10.1111/imm.12116
10.1038/mt.2009.156
10.1016/j.vetimm.2016.12.003
10.1128/JVI.02184-14
10.1158/1078-0432.CCR-16-0477
10.1371/journal.pone.0097495
10.1093/jnci/djm102
10.1093/jnci/95.9.652
10.1371/journal.pone.0097407
10.1038/nature03128
10.1200/JCO.2017.75.8219
10.1016/B978-0-12-398342-8.00003-3
10.1056/NEJMoa1716435
10.1093/neuonc/now002
10.1158/0008-5472.CAN-05-3497
10.1016/0168-1702(89)90026-9
10.1038/cgt.2014.13
10.1038/mt.2008.162
10.1016/j.cell.2013.09.034
10.1073/pnas.1303607110
10.1038/cgt.2009.6
ContentType Journal Article
Copyright The Author(s) 2021. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com 2021
Copyright_xml – notice: The Author(s) 2021. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com 2021
DBID AAYXX
CITATION
7X8
5PM
DOI 10.1093/neuonc/noab128
DatabaseName CrossRef
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic
CrossRef
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1523-5866
EndPage 1921
ExternalDocumentID 10_1093_neuonc_noab128
10.1093/neuonc/noab128
GrantInformation_xml – fundername: ;
– fundername: ;
  grantid: CA247970
– fundername: ;
  grantid: P30CA16672; NCI# CA0166772
GroupedDBID ---
.2P
.I3
.XZ
.ZR
0R~
123
18M
1TH
29N
2WC
36B
4.4
48X
53G
5VS
5WD
70D
AABZA
AACZT
AAJKP
AAJQQ
AAMDB
AAMVS
AAOGV
AAPNW
AAPQZ
AAPXW
AARHZ
AASNB
AAUAY
AAUQX
AAVAP
ABEUO
ABIXL
ABJNI
ABKDP
ABNHQ
ABNKS
ABPTD
ABQLI
ABQNK
ABWST
ABXVV
ABZBJ
ACGFO
ACGFS
ACUFI
ACUTO
ACYHN
ADBBV
ADEYI
ADGZP
ADHKW
ADHZD
ADIPN
ADJQC
ADOCK
ADQBN
ADRIX
ADRTK
ADVEK
ADYVW
ADZXQ
AEGPL
AEGXH
AEJOX
AEKSI
AEMDU
AENEX
AENZO
AEPUE
AETBJ
AEWNT
AFFZL
AFIYH
AFOFC
AFXAL
AFXEN
AGINJ
AGKEF
AGQXC
AGSYK
AGUTN
AHXPO
AIAGR
AIJHB
AJEEA
AKWXX
ALMA_UNASSIGNED_HOLDINGS
ALUQC
AOIJS
APIBT
APWMN
ATGXG
AXUDD
BAWUL
BAYMD
BCRHZ
BEYMZ
BHONS
BTRTY
BVRKM
C45
CDBKE
CS3
CZ4
DAKXR
DIK
DILTD
DU5
D~K
E3Z
EBS
EE~
EJD
EMB
EMOBN
ENERS
F5P
F9B
FECEO
FLUFQ
FOEOM
FOTVD
FQBLK
GAUVT
GJXCC
GX1
H13
H5~
HAR
HW0
HYE
HZ~
IOX
J21
KBUDW
KOP
KQ8
KSI
KSN
M49
MHKGH
N9A
NGC
NOMLY
NOYVH
NU-
O0~
O9-
OAUYM
OAWHX
OCZFY
ODMLO
OJQWA
OJZSN
OK1
OPAEJ
OVD
OWPYF
P2P
P6G
PAFKI
PEELM
Q1.
Q5Y
RD5
RHF
ROX
RPM
RUSNO
RW1
RXO
SV3
TEORI
TJX
TR2
UDS
W8F
WOQ
X7H
YAYTL
YKOAZ
YXANX
~91
AAYXX
CITATION
7X8
5PM
ID FETCH-LOGICAL-c401t-351777314a01f90215206c7bf2fbc9dc85330dd60cf80ab13ed7e9e364e89f093
IEDL.DBID RPM
ISSN 1522-8517
IngestDate Tue Sep 17 21:24:01 EDT 2024
Fri Aug 16 20:54:08 EDT 2024
Fri Aug 23 01:43:15 EDT 2024
Wed Aug 28 03:17:10 EDT 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 11
Keywords immune-competent model
glioma
oncolytic adenovirus
Language English
License This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c401t-351777314a01f90215206c7bf2fbc9dc85330dd60cf80ab13ed7e9e364e89f093
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0003-3163-480X
OpenAccessLink https://academic.oup.com/neuro-oncology/article-pdf/23/11/1911/41064117/noab128.pdf
PMID 34059921
PQID 2535827747
PQPubID 23479
PageCount 11
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_8563315
proquest_miscellaneous_2535827747
crossref_primary_10_1093_neuonc_noab128
oup_primary_10_1093_neuonc_noab128
PublicationCentury 2000
PublicationDate 20211102
PublicationDateYYYYMMDD 2021-11-02
PublicationDate_xml – month: 11
  year: 2021
  text: 20211102
  day: 02
PublicationDecade 2020
PublicationPlace US
PublicationPlace_xml – name: US
PublicationTitle Neuro-oncology (Charlottesville, Va.)
PublicationYear 2021
Publisher Oxford University Press
Publisher_xml – name: Oxford University Press
References Boehm (2021110300462725700_CIT0018) 2005; 25
Forsyth (2021110300462725700_CIT0006) 2018; 36
Cloughesy (2021110300462725700_CIT0002) 2018; 20
Lal (2021110300462725700_CIT0014) 2000; 92
Dhar (2021110300462725700_CIT0016) 2009; 17
Brennan (2021110300462725700_CIT0019) 2013; 155
Crosby (2021110300462725700_CIT0015) 2015; 89
Li (2021110300462725700_CIT0029) 2017; 23
Pitter (2021110300462725700_CIT0031) 2016; 139
Jiang (2021110300462725700_CIT0008) 2014; 9
Killela (2021110300462725700_CIT0020) 2013; 110
Chitadze (2021110300462725700_CIT0025) 2017; 6
Lang (2021110300462725700_CIT0005) 2018; 36
Jiang (2021110300462725700_CIT0007) 2007; 99
Mason (2021110300462725700_CIT0026) 2017; 132
Blair (2021110300462725700_CIT0009) 1989; 14
Jiang (2021110300462725700_CIT0022) 2017; 77
Dhar (2021110300462725700_CIT0027) 2014; 21
Singh (2021110300462725700_CIT0021) 2004; 432
Kleijn (2021110300462725700_CIT0030) 2014; 9
Thomas (2021110300462725700_CIT0028) 2008; 16
Desjardins (2021110300462725700_CIT0001) 2018; 379
Rees (2021110300462725700_CIT0024) 2017; 183
Ying (2021110300462725700_CIT0010) 2009; 16
Pino (2021110300462725700_CIT0017) 2011
Thomas (2021110300462725700_CIT0013) 2006; 66
Wold (2021110300462725700_CIT0023) 2012; 115
Wheeler (2021110300462725700_CIT0003) 2016; 18
Prescott (2021110300462725700_CIT0011) 2015; 212
Fueyo (2021110300462725700_CIT0004) 2003; 95
Prescott (2021110300462725700_CIT0012) 2013; 140
References_xml – volume: 6
  start-page: e1358839
  issue: 11
  year: 2017
  ident: 2021110300462725700_CIT0025
  article-title: In-depth immunophenotyping of patients with glioblastoma multiforme: Impact of steroid treatment
  publication-title: Oncoimmunology.
  doi: 10.1080/2162402X.2017.1358839
  contributor:
    fullname: Chitadze
– volume: 132
  start-page: 463
  issue: 3
  year: 2017
  ident: 2021110300462725700_CIT0026
  article-title: Neutrophil-lymphocyte ratio dynamics during concurrent chemo-radiotherapy for glioblastoma is an independent predictor for overall survival
  publication-title: J Neurooncol.
  doi: 10.1007/s11060-017-2395-y
  contributor:
    fullname: Mason
– volume: 36
  start-page: 1440
  issue: 14
  year: 2018
  ident: 2021110300462725700_CIT0006
  article-title: Oncolytic Virotherapy for Malignant Gliomas
  publication-title: J Clin Oncol.
  doi: 10.1200/JCO.2017.77.3192
  contributor:
    fullname: Forsyth
– volume: 77
  start-page: 3894
  issue: 14
  year: 2017
  ident: 2021110300462725700_CIT0022
  article-title: Oncolytic Adenovirus and Tumor-Targeting Immune Modulatory Therapy Improve Autologous Cancer Vaccination
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-17-0468
  contributor:
    fullname: Jiang
– volume: 92
  start-page: 326
  issue: 2
  year: 2000
  ident: 2021110300462725700_CIT0014
  article-title: An implantable guide-screw system for brain tumor studies in small animals
  publication-title: J Neurosurg.
  doi: 10.3171/jns.2000.92.2.0326
  contributor:
    fullname: Lal
– volume: 25
  start-page: 6464
  issue: 15
  year: 2005
  ident: 2021110300462725700_CIT0018
  article-title: Transformation of human and murine fibroblasts without viral oncoproteins
  publication-title: Mol Cell Biol.
  doi: 10.1128/MCB.25.15.6464-6474.2005
  contributor:
    fullname: Boehm
– volume: 212
  start-page: S271
  year: 2015
  ident: 2021110300462725700_CIT0011
  article-title: Natural Immunity to Ebola Virus in the Syrian Hamster Requires Antibody Responses
  publication-title: J Infect Dis.
  doi: 10.1093/infdis/jiv203
  contributor:
    fullname: Prescott
– volume: 20
  start-page: 1383
  issue: 10
  year: 2018
  ident: 2021110300462725700_CIT0002
  article-title: Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC
  publication-title: Neuro Oncol.
  doi: 10.1093/neuonc/noy075
  contributor:
    fullname: Cloughesy
– volume: 139
  start-page: 1458
  issue: Pt 5
  year: 2016
  ident: 2021110300462725700_CIT0031
  article-title: Corticosteroids compromise survival in glioblastoma
  publication-title: Brain.
  doi: 10.1093/brain/aww046
  contributor:
    fullname: Pitter
– volume: 140
  start-page: 168
  issue: 2
  year: 2013
  ident: 2021110300462725700_CIT0012
  article-title: The adaptive immune response does not influence hantavirus disease or persistence in the Syrian hamster
  publication-title: Immunology.
  doi: 10.1111/imm.12116
  contributor:
    fullname: Prescott
– volume: 17
  start-page: 1724
  issue: 10
  year: 2009
  ident: 2021110300462725700_CIT0016
  article-title: Pre-existing immunity and passive immunity to adenovirus 5 prevents toxicity caused by an oncolytic adenovirus vector in the Syrian hamster model
  publication-title: Mol Ther.
  doi: 10.1038/mt.2009.156
  contributor:
    fullname: Dhar
– volume: 183
  start-page: 40
  year: 2017
  ident: 2021110300462725700_CIT0024
  article-title: Characterisation of monoclonal antibodies specific for hamster leukocyte differentiation molecules
  publication-title: Vet Immunol Immunopathol.
  doi: 10.1016/j.vetimm.2016.12.003
  contributor:
    fullname: Rees
– volume: 89
  start-page: 669
  issue: 1
  year: 2015
  ident: 2021110300462725700_CIT0015
  article-title: Amplified and persistent immune responses generated by single-cycle replicating adenovirus vaccines
  publication-title: J Virol.
  doi: 10.1128/JVI.02184-14
  contributor:
    fullname: Crosby
– start-page: 2348
  issue: 48
  year: 2011
  ident: 2021110300462725700_CIT0017
  article-title: Isolation of brain and spinal cord mononuclear cells using percoll gradients
  publication-title: J Vis Exp
  contributor:
    fullname: Pino
– volume: 23
  start-page: 239
  issue: 1
  year: 2017
  ident: 2021110300462725700_CIT0029
  article-title: The Efficacy of Oncolytic Adenovirus Is Mediated by T-cell Responses against Virus and Tumor in Syrian Hamster Model
  publication-title: Clin Cancer Res.
  doi: 10.1158/1078-0432.CCR-16-0477
  contributor:
    fullname: Li
– volume: 9
  start-page: e97495
  issue: 5
  year: 2014
  ident: 2021110300462725700_CIT0030
  article-title: The in vivo therapeutic efficacy of the oncolytic adenovirus Delta24-RGD is mediated by tumor-specific immunity
  publication-title: PLoS One.
  doi: 10.1371/journal.pone.0097495
  contributor:
    fullname: Kleijn
– volume: 99
  start-page: 1410
  issue: 18
  year: 2007
  ident: 2021110300462725700_CIT0007
  article-title: Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: role of autophagic cell death
  publication-title: J Natl Cancer Inst.
  doi: 10.1093/jnci/djm102
  contributor:
    fullname: Jiang
– volume: 95
  start-page: 652
  issue: 9
  year: 2003
  ident: 2021110300462725700_CIT0004
  article-title: Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway
  publication-title: J Natl Cancer Inst.
  doi: 10.1093/jnci/95.9.652
  contributor:
    fullname: Fueyo
– volume: 9
  start-page: e97407
  issue: 5
  year: 2014
  ident: 2021110300462725700_CIT0008
  article-title: Delta-24-RGD oncolytic adenovirus elicits anti-glioma immunity in an immunocompetent mouse model
  publication-title: PLoS One.
  doi: 10.1371/journal.pone.0097407
  contributor:
    fullname: Jiang
– volume: 432
  start-page: 396
  issue: 7015
  year: 2004
  ident: 2021110300462725700_CIT0021
  article-title: Identification of human brain tumour initiating cells
  publication-title: Nature.
  doi: 10.1038/nature03128
  contributor:
    fullname: Singh
– volume: 36
  issue: 14
  year: 2018
  ident: 2021110300462725700_CIT0005
  article-title: Phase I study of DNX-2401 (Delta-24-RGD) oncolytic adenovirus: replication and immunotherapeutic effects in recurrent malignant glioma
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2017.75.8219
  contributor:
    fullname: Lang
– volume: 115
  start-page: 69
  year: 2012
  ident: 2021110300462725700_CIT0023
  article-title: Chapter three–Syrian hamster as an animal model to study oncolytic adenoviruses and to evaluate the efficacy of antiviral compounds
  publication-title: Adv Cancer Res.
  doi: 10.1016/B978-0-12-398342-8.00003-3
  contributor:
    fullname: Wold
– volume: 379
  start-page: 150
  issue: 2
  year: 2018
  ident: 2021110300462725700_CIT0001
  article-title: Recurrent glioblastoma treated with recombinant poliovirus
  publication-title: N Engl J Med.
  doi: 10.1056/NEJMoa1716435
  contributor:
    fullname: Desjardins
– volume: 18
  start-page: 1137
  issue: 8
  year: 2016
  ident: 2021110300462725700_CIT0003
  article-title: Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma
  publication-title: Neuro Oncol.
  doi: 10.1093/neuonc/now002
  contributor:
    fullname: Wheeler
– volume: 66
  start-page: 1270
  issue: 3
  year: 2006
  ident: 2021110300462725700_CIT0013
  article-title: Syrian hamster as a permissive immunocompetent animal model for the study of oncolytic adenovirus vectors
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-05-3497
  contributor:
    fullname: Thomas
– volume: 14
  start-page: 339
  issue: 4
  year: 1989
  ident: 2021110300462725700_CIT0009
  article-title: Restricted replication of human adenovirus type 5 in mouse cell lines
  publication-title: Virus Res.
  doi: 10.1016/0168-1702(89)90026-9
  contributor:
    fullname: Blair
– volume: 21
  start-page: 171
  issue: 4
  year: 2014
  ident: 2021110300462725700_CIT0027
  article-title: Cycles of transient high-dose cyclophosphamide administration and intratumoral oncolytic adenovirus vector injection for long-term tumor suppression in Syrian hamsters
  publication-title: Cancer Gene Ther.
  doi: 10.1038/cgt.2014.13
  contributor:
    fullname: Dhar
– volume: 16
  start-page: 1665
  issue: 10
  year: 2008
  ident: 2021110300462725700_CIT0028
  article-title: Immunosuppression enhances oncolytic adenovirus replication and antitumor efficacy in the Syrian hamster model
  publication-title: Mol Ther.
  doi: 10.1038/mt.2008.162
  contributor:
    fullname: Thomas
– volume: 155
  start-page: 462
  issue: 2
  year: 2013
  ident: 2021110300462725700_CIT0019
  article-title: The somatic genomic landscape of glioblastoma
  publication-title: Cell.
  doi: 10.1016/j.cell.2013.09.034
  contributor:
    fullname: Brennan
– volume: 110
  start-page: 6021
  issue: 15
  year: 2013
  ident: 2021110300462725700_CIT0020
  article-title: TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal
  publication-title: Proc Natl Acad Sci U S A.
  doi: 10.1073/pnas.1303607110
  contributor:
    fullname: Killela
– volume: 16
  start-page: 625
  issue: 8
  year: 2009
  ident: 2021110300462725700_CIT0010
  article-title: INGN 007, an oncolytic adenovirus vector, replicates in Syrian hamsters but not mice: comparison of biodistribution studies
  publication-title: Cancer Gene Ther.
  doi: 10.1038/cgt.2009.6
  contributor:
    fullname: Ying
SSID ssj0021561
Score 2.4143467
Snippet Abstract Background Oncolytic adenoviruses are promising new treatments against solid tumors, particularly for glioblastoma (GBM), and preclinical models are...
BACKGROUNDOncolytic adenoviruses are promising new treatments against solid tumors, particularly for glioblastoma (GBM), and preclinical models are required to...
SourceID pubmedcentral
proquest
crossref
oup
SourceType Open Access Repository
Aggregation Database
Publisher
StartPage 1911
SubjectTerms Basic and Translational Investigations
Title An immune-competent, replication-permissive Syrian Hamster glioma model for evaluating Delta-24-RGD oncolytic adenovirus
URI https://search.proquest.com/docview/2535827747
https://pubmed.ncbi.nlm.nih.gov/PMC8563315
Volume 23
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB61PVS9IJ5ioVQGIXEhTWLHdnKsWsoCKkJApd4i27FLpF1ntZut6L9nnMeKnJA45yFnZuJ8k_nmG4C3zjAqteARE6rCBEXjK-V4FbGcc2YlD5NRAtviq5hfZ59v-M0e8LEXpiPtG12f-sXy1Ne_Om7lamnikScWf7s6z7lgLOXxPuxLxsYUfciyMCHpRVIxywqD53dKjSz2dtt4E_tGadyWj-CQZUGehKaTj9Kk0S3gzSlb8q_Pz-VDeDDgRnLWr-8R7Fn_GA6vhsr4E_h95kkdej1sZAYo3L4na7srT0erQHvZBLY6-XGPYefJXC2DTAK5XdTNUpFuKA5BEEtGCXB_Sy7solURzaLvHy8IPlazuMcVEIXbVXNXr7ebp3B9-eHn-TwapipEBnOpNlD3pZQszVSSuqKba5sII7WjTpuiMnngm1aVSIzLEzQUs5W0hWUis3nh0IzP4MA33j4HwpgI8KkwiLoyp5y2NBeOaeqsSVTKZ_BuNGu56sUzyr7ozcreF-Xgixm8Qav_86TXo1NKNFiobChvm-2mpDw0_CKSlTOQE2_tbhlktKdHMLo6Oe0hml7895Uv4YgGpkv42UyP4aBdb-0rhCqtPkGQ_unLSRegfwCx-u3P
link.rule.ids 230,315,733,786,790,891,27955,27956,53825,53827
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LbtQwFL0qRSrd8K6Y8jIIiQ2ZJHacZJZVSxmgUyFoUXeR7dgl6owzmkkQ5eu5zmNE2CBY5yHHx49z43PPBXhlFKOJjLnHYpFjgCJxShmeeyzlnOmEu8ooTm1xGk_Pow8X_GILeJ8L04j2lSzGdr4Y2-Jbo61cLpTf68T8T7PDlMeMhdy_ATdxvlLeB-ldnIUhSWuTinGWKz2_8WpkvtV1aZVvSyFxYd6FHRY5gxIaDralQaqbY5xDveRvG9DxHfjaN73VnVyN60qO1c8_XB3_-dvuwu2OkpKD9vI92NL2PuzMukP3B_DjwJLCpZFoT3Usu3pDVnpz8u0tnaJm7YTw5Ms1jmhLpmLhHBjI5bwoF4I09XYI8mPSu4vbS3Kk55XwaOR9fndEsL_K-TW2gAhcCcvvxapeP4Tz47dnh1OvK9jgKQzTKpcVkCQJCyMRhGbSlMwNYpVIQ41Uk1ylTsqa53GgTBogAkzniZ5oFkc6nRjEZw-2bWn1IyCMxY6ZTRQSusgIIzVNY8MkNVoFIuQjeN3jlS1bX46sPU9nWQty1oE8gpcI519vetGjnWGHuUMTYXVZrzPKXS4xkuRkBMlgGGxe6Ry6h1cQ3MapuwNz_7-ffA63pmezk-zk_enHx7BLnaDG_dOmT2C7WtX6KTKiSj5rxv8vTVgO2g
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwGLVgSNVeYNy0AhsGIfFCmsSO4-RxWinlsmkCJk28RLZjj4jWqdoEMX79PudSLbwg7TlO5OT4cr58x-dD6I1RlHAZM4_GIocARcKUMiz3aMIY1Zy5yihObXEaz8-jTxfs4kapr0a0r2QxsYvlxBY_G23laqn8Xifmn50cJyymNGT-Kjf-XXQP5izhfaDexVoQlrRWqRBrufLzW79G6ltdl1b5thQSFuddNKKRMykh4WBrGhx3c6xzqJm8sQnNHqAfffdb7cmvSV3Jifr7j7Pjrd5vD93vqCk-aps8RHe0fYRGJ13y_TH6c2Rx4Y6TaE91bLt6h9d6mwH3Vk5Zs3GCePztCka2xXOxdE4M-HJRlEuBm7o7GHgy7l3G7SWe6kUlPBJ5Xz9MMXyzcnEFPcACVsTyd7GuN0_Q-ez99-O51xVu8BSEa5U7HcA5p2EkgtCkTencIFZcGmKkSnOVOElrnseBMkkAKFCdc51qGkc6SQ1g9BTt2NLqfYQpjR1DSxUQu8gIIzVJYkMlMVoFImRj9LbHLFu1_hxZm1enWQt01gE9Rq8B0v82etUjnsEHc8kTYXVZbzLC3JliIMt8jPhgKGwf6Zy6h1cA4MaxuwP02a3vfIlGZ9NZ9uXj6efnaJc4XY37tU1eoJ1qXesDIEaVPGymwDWrThFa
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=An+immune-competent%2C+replication-permissive+Syrian+Hamster+glioma+model+for+evaluating+Delta-24-RGD+oncolytic+adenovirus&rft.jtitle=Neuro-oncology+%28Charlottesville%2C+Va.%29&rft.au=Phillips%2C+Lynette+M&rft.au=Li%2C+Shoudong&rft.au=Gumin%2C+Joy&rft.au=Daou%2C+Marc&rft.date=2021-11-02&rft.pub=Oxford+University+Press&rft.issn=1522-8517&rft.eissn=1523-5866&rft.volume=23&rft.issue=11&rft.spage=1911&rft.epage=1921&rft_id=info:doi/10.1093%2Fneuonc%2Fnoab128&rft.externalDocID=10.1093%2Fneuonc%2Fnoab128
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1522-8517&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1522-8517&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1522-8517&client=summon